Mark Cuban's Company Introduces Affordable Biosimilar to J&J’s Stelara

Mark Cuban Cost Plus Drug Company aims to disrupt pharmaceutical pricing by offering a biosimilar version of Stelara, a popular drug by Johnson & Johnson, potentially making the treatment more affordable for patients.